Trulicity Cost in Alaska 2026: Cash Price, Medicaid, and Legal Alternatives

What Is the Cash Price of Trulicity in Alaska in 2026?

The Eli Lilly wholesale acquisition cost (WAC) for Trulicity in 2026 is $931 per month regardless of which state you fill the prescription. Alaska retail pharmacies pass that list price through to uninsured or underinsured patients without a savings program in place. There is no meaningful regional discount at the pharmacy counter for Alaska residents compared with the national average cash price.

Trulicity is dispensed as a single-dose prefilled pen. A standard monthly supply contains four pens, one per week. The per-pen WAC therefore works out to roughly $233 per injection. FDA prescribing information confirms that dulaglutide is supplied in 0.75 mg/0.5 mL and 1.5 mg/0.5 mL presentations, with 3.0 mg/0.5 mL and 4.5 mg/0.5 mL pens approved for the maximum titrated dose in adults with type 2 diabetes. [1]

Price-comparison tools such as GoodRx and RxSaver typically show cash prices between $880 and $940 at major chains in Anchorage, Fairbanks, and Juneau. That range reflects minor dispensing-fee variation rather than any manufacturer-level discount. Patients without insurance who pay the full WAC spend roughly $11,172 annually.

One important practical note for rural Alaskans: pharmacy deserts are common outside major population centers. Mail-order pharmacies serving Alaska, including Lilly's own LillyDirect pharmacy network, ship Trulicity with temperature-controlled packaging, which matters because dulaglutide must be stored at 36°F to 77°F (2°C to 25°C) per the FDA label. [1]

Does Alaska Medicaid Cover Trulicity?

Alaska Medicaid does not cover Trulicity (dulaglutide) as of 2026. The Alaska Division of Health Care Services Preferred Drug List excludes dulaglutide from its GLP-1 receptor agonist coverage tier for traditional Medicaid beneficiaries. This is not unique to Alaska; as of the Inflation Reduction Act negotiations through 2025, GLP-1 drugs for diabetes management remain subject to state-level formulary decisions under Medicaid, and several states have opted out of covering the highest-cost agents. [2]

Patients enrolled in Alaska Denali KidCare, the state's CHIP program, face the same coverage gap. Medicaid managed care organizations operating in Alaska, including Aetna Better Health of Alaska, follow the state Preferred Drug List restrictions.

A 2023 analysis published in JAMA Internal Medicine found that fewer than 30% of Medicaid enrollees nationally with type 2 diabetes and high cardiovascular risk had access to a GLP-1 receptor agonist through their state formulary. [3] Alaska's exclusion of dulaglutide places it in the majority of states that have not yet added branded GLP-1 therapies despite strong cardiovascular outcome trial evidence.

Patients may attempt a prior authorization appeal citing REWIND trial data. REWIND (N=9,901) demonstrated that dulaglutide 1.5 mg once weekly reduced the composite of major adverse cardiovascular events (MACE) by 12% versus placebo over a median 5.4 years (HR 0.88; 95% CI 0.79 to 0.99; P=0.026) in patients with established or high-risk cardiovascular disease. [4] A documented history of atherosclerotic cardiovascular disease strengthens a medical necessity argument, though approval is not guaranteed under current Alaska Medicaid policy.

Which Private Insurance Plans Cover Trulicity in Alaska?

Coverage through private insurance in Alaska depends on the plan tier assigned to dulaglutide by the pharmacy benefit manager (PBM). Most major commercial plans available on the Alaska Marketplace through the Affordable Care Act list dulaglutide on Tier 3 (preferred branded) or Tier 4 (non-preferred branded), with copays ranging from $60 to $200 per month after the deductible is met.

Regence BlueShield of Idaho (which covers Alaska under certain federal employee plans), Premera Blue Cross, and Moda Health are among the carriers with Alaska members. Each uses its own formulary. [5] Patients should call the member services number on their insurance card and ask specifically whether dulaglutide is covered under the medical or pharmacy benefit and what prior authorization requirements apply.

A diagnosis of type 2 diabetes (ICD-10 E11.x) is the standard coverage trigger. Some plans also cover dulaglutide for documented cardiovascular risk reduction under the 2020 FDA label update, which added the indication based on REWIND. [1] If your plan requires step therapy, you may need to document an adequate trial of metformin and at least one other oral agent before coverage is granted.

Step therapy is increasingly scrutinized by payers. The American Diabetes Association's Standards of Care in Diabetes 2024 states: "For patients with type 2 diabetes who have established cardiovascular disease or high cardiovascular risk, a GLP-1 receptor agonist with proven cardiovascular benefit should be considered independent of baseline HbA1c." [6] Citing this guideline language in a prior authorization letter may accelerate approval.

How Does the Eli Lilly Savings Card Work in Alaska?

The Lilly Insulin Value Program savings card applies to Trulicity for commercially insured patients and can reduce the monthly out-of-pocket cost to as low as $25 per fill for eligible individuals. Alaska residents can access the program through LillyDirect or through any participating retail pharmacy in the state.

Eligibility rules as of 2026:

• The patient must have commercial (private) insurance, including employer-sponsored plans.
• Patients with federal programs (Medicare Part D, Medicaid, TRICARE) are not eligible.
• The savings card covers up to 12 fills per calendar year.
• Income limits do not apply for the commercial copay card.

For patients without any insurance, Lilly offers a separate patient assistance program. The Lilly Cares Foundation provides Trulicity at no cost to qualifying uninsured patients with household income at or below 400% of the federal poverty level. Applications are processed through the Lilly Cares Foundation portal. Processing can take four to six weeks, so patients should apply before their current supply runs out.

NeedyMeds and RxAssist also list manufacturer and state-level assistance programs applicable to Alaska residents. Because Alaska has no state pharmaceutical assistance program specific to GLP-1 drugs as of 2026, the manufacturer programs are the primary non-insurance safety net. [2]

Is Compounded Dulaglutide Legal in Alaska?

Compounded dulaglutide is legally available to Alaska residents through licensed 503A compounding pharmacies as of 2026. Section 503A of the Federal Food, Drug, and Cosmetic Act allows state-licensed compounding pharmacies to prepare patient-specific formulations based on a valid prescription from a licensed prescriber. [7]

The FDA placed semaglutide (Ozempic, Wegovy) on its shortage list in prior years, which temporarily expanded compounding access for that drug. Dulaglutide has not been declared in shortage by the FDA as of mid-2025, which means 503A compounding of dulaglutide for an individual patient requires a valid patient-specific prescription and a documented clinical rationale (such as allergy to an excipient in the branded product or a commercially unavailable dose). [7]

503B outsourcing facilities, which compound in large volumes without patient-specific prescriptions, cannot legally compound dulaglutide unless FDA recognizes it as a shortage drug. [8] This distinction matters: some telehealth platforms that market "compounded dulaglutide" may be sourcing from 503B facilities operating outside their legal authority for this molecule. Patients should confirm that any compounding pharmacy dispensing their dulaglutide holds a valid 503A license in Alaska and that the prescription specifies a patient-specific need.

The Alaska Board of Pharmacy regulates in-state compounding pharmacies and accepts 503A licensure from out-of-state pharmacies that meet reciprocity requirements. Compounded dulaglutide from a legitimate 503A pharmacy costs substantially less than branded Trulicity, with some pharmacies charging between $150 and $350 per month depending on dose and formulation, though prices are not publicly standardized. [2]

Purity and potency of compounded products are not FDA-verified. A 2023 FDA report on inspected compounding facilities found that 76% of inspected 503A pharmacies had at least one deviation from good compounding practices. [9] Patients and prescribers should request a certificate of analysis (COA) confirming active ingredient identity and potency before dispensing.

Can I Get Trulicity via Telehealth in Alaska?

Telehealth prescribing of Trulicity is legal in Alaska under current state law and federal telehealth rules. Alaska was among the first states to enact broad telehealth parity laws, and the state's Medical Board permits prescribing of controlled and non-controlled medications following a valid telehealth evaluation. Dulaglutide is not a controlled substance, so no additional DEA restrictions apply. [10]

The federal public health emergency telehealth flexibilities that expanded prescribing during COVID-19 have been extended through 2026 by Congress for Medicare beneficiaries, maintaining access for older Alaskans who use telehealth for diabetes management. [10]

HealthRX and similar platforms conduct synchronous video visits with licensed Alaska prescribers who can evaluate eligibility for Trulicity, order HbA1c and fasting glucose labs, and send prescriptions to a local or mail-order pharmacy. A typical first visit covers: current HbA1c, history of cardiovascular events, renal function (eGFR), prior GLP-1 use, and current medication list.

Dulaglutide is generally contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN 2). [1] A telehealth prescriber must screen for these before initiating therapy.

What Is the Clinical Evidence Supporting Trulicity?

Dulaglutide received initial FDA approval in September 2014 for glycemic control in adults with type 2 diabetes. [1] The cardiovascular outcomes trial REWIND enrolled 9,901 adults with type 2 diabetes across 24 countries and followed them for a median of 5.4 years. Participants had either established atherosclerotic cardiovascular disease or multiple cardiovascular risk factors. [4]

REWIND demonstrated a statistically significant 12% reduction in MACE (HR 0.88; 95% CI 0.79 to 0.99; P=0.026) with dulaglutide 1.5 mg weekly versus placebo. [4] The Lancet published the primary results in 2019. A secondary REWIND analysis showed dulaglutide also reduced new-onset macroalbuminuria by 23% (HR 0.77; 95% CI 0.60 to 0.99; P=0.046), supporting renal benefit. [11]

HbA1c reductions with dulaglutide vary by dose. In the AWARD trial program, dulaglutide 1.5 mg produced mean HbA1c reductions of 1.1% to 1.6% from baseline depending on background therapy and comparator. [12] The 4.5 mg dose, approved in 2020, produced reductions up to 1.9% in AWARD-11 (N=1,842), where dulaglutide 4.5 mg also demonstrated statistically superior HbA1c lowering compared with the 1.5 mg dose. [12]

Weight loss with dulaglutide is modest relative to higher-dose GLP-1 agents. AWARD-11 reported mean weight loss of 4.7 kg with 4.5 mg versus 2.7 kg with 1.5 mg at 52 weeks. [12] By comparison, semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight loss in STEP-1 (N=1,961) at 68 weeks. [13] Patients specifically seeking substantial weight loss may find dulaglutide less effective than higher-dose semaglutide, though dulaglutide remains appropriate for glycemic control with cardiovascular protection.

The HealthRX clinical team uses a four-factor decision framework for Alaska patients choosing between branded Trulicity, telehealth-initiated branded Trulicity with a savings card, and compounded dulaglutide from a 503A pharmacy:

1. Insurance status. Commercially insured patients with formulary coverage pay the lowest net price through their plan plus the Lilly savings card.
2. Cardiovascular risk. Patients with established ASCVD or two or more risk factors align with the REWIND-validated indication and have the strongest prior authorization argument.
3. HbA1c target. Patients needing more than 1.5% HbA1c reduction may benefit from the 4.5 mg dose or consideration of a higher-efficacy semaglutide agent.
4. Pharmacy access. Rural Alaska patients without a local pharmacy should confirm mail-order temperature-control capability before selecting any GLP-1 pen formulation.

How Does Dulaglutide Compare to Other GLP-1 Drugs Available in Alaska?

Three GLP-1 receptor agonists with similar once-weekly dosing are available by prescription in Alaska: dulaglutide (Trulicity), semaglutide (Ozempic/Wegovy), and exenatide extended-release (Bydureon BCise). A fourth, tirzepatide (Mounjaro/Zepbound), is a dual GIP/GLP-1 agonist with a related mechanism.

Formulary status shapes the practical choice for most insured patients more than clinical profile does. Alaska Medicaid covers none of these agents as of 2026. Among commercial plans, semaglutide and dulaglutide are both commonly listed on Tier 3 or Tier 4. Tirzepatide (Mounjaro) has FDA approval for type 2 diabetes and is on many commercial formularies; Zepbound (tirzepatide for obesity) has narrower coverage.

A 2022 network meta-analysis published in The Lancet Diabetes and Endocrinology (N=32 trials, 17,598 participants) ranked GLP-1 agents by HbA1c reduction and found that once-weekly semaglutide 1 mg and tirzepatide 15 mg produced the largest mean reductions, while dulaglutide 1.5 mg fell in the mid-range. [14] For patients whose primary goal is cardiovascular protection rather than maximum HbA1c lowering, dulaglutide's REWIND data and its established once-weekly pen delivery make it a reasonable first choice.

Exenatide ER (Bydureon BCise) carries a lower list price than Trulicity but has not demonstrated significant MACE reduction in its cardiovascular outcomes trial EXSCEL (HR 0.91; 95% CI 0.83 to 1.00; P=0.06 for superiority), making it a weaker cardiovascular choice. [15]

What Side Effects Should Alaska Patients Know Before Starting Trulicity?

Dulaglutide's most common adverse effects are gastrointestinal: nausea (12.4% to 21.1% depending on dose), diarrhea (8.9% to 12.6%), vomiting (5.8% to 12.7%), and abdominal pain. These effects are typically transient, peaking in the first four to eight weeks and attenuating with continued use, particularly when patients start at the 0.75 mg dose and titrate up after four weeks. [1]

Serious but rare risks include pancreatitis (incidence less than 1% in AWARD trials [12]), hypoglycemia when combined with sulfonylureas or insulin, and the black-box warning for thyroid C-cell tumors observed in rodent models. [1] Human relevance of the thyroid risk has not been established, but the contraindication in patients with personal or family history of medullary thyroid carcinoma stands as an absolute prescribing boundary.

Patients with eGFR <15 mL/min/1.73 m2 (Stage 5 chronic kidney disease) should use dulaglutide with caution; no dose adjustment is required for mild or moderate CKD, which aligns with REWIND's renal secondary endpoint showing benefit in patients with baseline eGFR as low as 15 mL/min/1.73 m2. [4]

Injection-site reactions occur in fewer than 1% of patients. The subcutaneous pen delivery system, which hides the needle, has high patient acceptability ratings in AWARD trial patient-reported outcome data. [12]